Related Experiment Video
Updated: Apr 4, 2026
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT
Amelie Schramm1, Thomas W P Friedl2, Fabienne Schochter2
1Gynecology and Obstetrics, University Hospital Ulm, Prittwitzstraße 43, 89075, Ulm, Germany. Amelie.Schramm@uniklinik-ulm.de.
Purpose:
The aim of the ongoing DETECT study program is to evaluate therapeutic intervention based on phenotypes of circulating tumor cells (CTC) in patients with metastatic breast cancer (MBC). Currently (as of July 2015) more than half of the projected about 2000 patients with MBC have already been screened for CTC.
Methods:
Women with HER2-negative primary tumor and presence of CTC are recruited into different DETECT trials according to the HER2-phenotype of CTC. Patients with HER2-positive CTC are randomized to treatment with physicians' choice therapy (standard chemo- or endocrine therapy) with or without additional HER2-targeted therapy with lapatinib in the DETECT III trial. In DETECT IVa, postmenopausal patients with hormone-receptor positive primary cancer and HER2-negative CTC receive everolimus and standard endocrine therapy. For women with HER2-negative CTC and triple negative MBC or hormone-receptor positive tumor and indication for chemotherapy, a treatment with eribulin is offered (DETECT IVb). The clinical efficacy is investigated by CTC-Clearance and progression-free survival (PFS). The DETECT V/CHEVENDO trial extends the DETECT study program for women with HER2-positive and hormone-receptor positive MBC. The primary objective of this trial is to compare safety and quality of life (QoL) as assessed by the occurrence of adverse events in patients treated with dual (trastuzumab plus pertuzumab) HER2-targeted therapy plus either endocrine or chemotherapy. The translational research projects of the DETECT study program focus on further molecular characterization of CTC and evaluation of markers for their suitability to predict treatment response and to facilitate the development of more personalized treatment options.
Insights
The DETECT study uses circulating tumor cell (CTC) phenotypes to guide metastatic breast cancer (MBC) treatment. This personalized approach aims to improve patient outcomes by tailoring therapies based on individual tumor cell characteristics.
Area of Science:
- Oncology
- Translational Research
- Clinical Trials
Background:
- Metastatic breast cancer (MBC) treatment can be improved by personalizing therapeutic interventions.
- Circulating tumor cells (CTCs) offer a window into tumor biology and potential therapeutic targets.
Purpose of the Study:
- To evaluate therapeutic interventions based on circulating tumor cell (CTC) phenotypes in patients with metastatic breast cancer (MBC).
- To screen approximately 2000 patients with MBC for CTCs within the ongoing DETECT study program.
Main Methods:
- Recruitment of women with HER2-negative primary tumors and CTCs into DETECT trials based on CTC HER2-phenotype.
- Randomization of patients with HER2-positive CTCs to standard therapy with or without lapatinib (DETECT III).
- Treatment with everolimus and endocrine therapy for postmenopausal patients with hormone-receptor positive primary cancer and HER2-negative CTCs (DETECT IVa).
- Treatment with eribulin for women with HER2-negative CTCs and triple-negative MBC or hormone-receptor positive tumor requiring chemotherapy (DETECT IVb).
- Investigation of clinical efficacy using CTC-Clearance and progression-free survival (PFS).
- Extension of the DETECT program (DETECT V/CHEVENDO) to compare safety and quality of life (QoL) in HER2-positive and hormone-receptor positive MBC patients receiving dual HER2-targeted therapy plus endocrine or chemotherapy.
- Focus on molecular characterization of CTCs and identification of predictive markers for treatment response.
Main Results:
- Over half of the projected 2000 MBC patients have been screened for CTCs as of July 2015.
- Multiple DETECT trials are actively recruiting and treating patients based on CTC phenotypes.
- Ongoing translational research aims to further characterize CTCs and identify predictive markers.
Conclusions:
- Therapeutic intervention guided by CTC phenotypes is a promising strategy for managing metastatic breast cancer.
- The DETECT study program is generating valuable data on personalized treatment approaches for MBC.
- Further research into CTCs holds potential for developing more effective and individualized treatment options for breast cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...